multiple myeloma (47)
antineoplastic combined chemotherapy protocols (17)
antineoplastic agents (10)
receptors, chimeric antigen (8)
lymphoma, non-hodgkin (6)
lymphoma (5)
neoplasm recurrence, local (5)
pyrimidines (5)
hematopoietic stem cell transplantation (4)
immunotherapy (4)
leukemia, lymphocytic, chronic, b-cell (4)
myelodysplastic syndromes (4)
antibodies, monoclonal (3)
azacitidine (3)
bone marrow transplantation (3)
diseases of the blood and blood-forming organs (3)
histone deacetylase inhibitors (3)
immunoconjugates (3)
leukemia, myeloid, acute (3)
non-hodgkins-lymphoma (3)
protein kinase inhibitors (3)
rc633-647.5 (3)
waldenstrom macroglobulinemia (3)
antibodies, bispecific (2)
antibodies, monoclonal, humanized (2)
azepines (2)
benzimidazoles (2)
chronic lymphocytic-leukemia (2)
dexamethasone (2)
drug resistance, neoplasm (2)
hodgkin disease (2)
hydrazines (2)
immunotherapy, adoptive (2)
myelodysplastic syndrome (2)
oligopeptides (2)
physicians (2)
practice guidelines as topic (2)
proteasome inhibitors (2)
salvage therapy (2)
triazoles (2)
acute myelogenous leukemia (1)
adoptive transfer (1)
allobmt (1)
anemia (1)
antibodies, neoplasm (1)
antibody-dependent cell cytotoxicity (1)
anti-cd20 monoclonal-antibody (1)
antigens, cd19 (1)
antimetabolites, antineoplastic (1)
antineoplastic agents, immunological (1)